6.17

5.65% 0.33

Atara Biotherapeutics Inc (ATRA)

Overview News Price History Option Chain Financials Why ATRA Down? Discussions Forecast

Atara Biotherapeutics Inc stock is traded at $6.17, with a volume of 23,959. It is up +5.65% in the last 24 hours and down -13.95% over the past month. Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Previous Close:

$5.84

Open:

$5.84

24h Volume:

23,959

Relative Volume:

0.14

Market Cap:

$34.27M

Revenue:

$100.44M

Net Income/Loss:

$-133.16M

P/E Ratio:

-0.2395

EPS:

-25.76

Net Cash Flow:

$-94.85M

1W Performance:

+16.42%

1M Performance:

-13.95%

6M Performance:

-34.22%

1Y Performance:

-65.48%

1-Day Range:

$5.62

$6.18

1-Week Range:

$5.1559

$6.18

52-Week Range:

$5.005

$19.00

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Name

Atara Biotherapeutics Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

805-623-4211

Address

1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA

Employee

153

Twitter

@Atarabio

Next Earnings Date

2024-11-18

Latest SEC Filings

ATRA's Discussions on Twitter

Compare ATRA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATRA Atara Biotherapeutics Inc	6.17	34.27M	100.44M	-133.16M	-94.85M	-25.76
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-09-23	Downgrade	Evercore ISI	Outperform → In-line
Nov-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-09-23	Downgrade	Mizuho	Buy → Neutral
Jul-20-22	Downgrade	Citigroup	Neutral → Sell
Jul-13-22	Downgrade	JP Morgan	Overweight → Neutral
Jul-13-22	Downgrade	Stifel	Buy → Hold
May-10-22	Downgrade	Citigroup	Buy → Neutral
May-13-21	Upgrade	JP Morgan	Neutral → Overweight
Dec-09-20	Downgrade	Citigroup	Buy → Neutral
Dec-08-20	Reiterated	H.C. Wainwright	Buy
Nov-10-20	Reiterated	H.C. Wainwright	Buy
Jun-30-20	Initiated	Evercore ISI	Outperform
Jun-15-20	Initiated	H.C. Wainwright	Buy
Apr-23-20	Upgrade	Citigroup	Neutral → Buy
Nov-08-19	Downgrade	JP Morgan	Overweight → Neutral
Sep-27-19	Downgrade	Goldman	Neutral → Sell
Sep-16-19	Downgrade	Jefferies	Buy → Hold
Jun-04-19	Upgrade	Citigroup	Sell → Neutral
May-30-19	Initiated	ROTH Capital	Buy
May-23-19	Initiated	Stifel	Buy
Jan-23-19	Initiated	Mizuho	Buy
Apr-10-18	Initiated	JP Morgan	Overweight
Mar-16-18	Initiated	Guggenheim	Neutral
Mar-05-18	Reiterated	Jefferies	Buy
Feb-28-18	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Feb-15-18	Downgrade	Citigroup	Neutral → Sell
Jan-03-18	Upgrade	Citigroup	Sell → Neutral
Oct-06-17	Resumed	Goldman	Neutral

View All

Atara Biotherapeutics Inc Stock (ATRA) Latest News

Apr 08, 2025

Trial misses sink cancer stocks in Q1: Mersana, Cargo, Mural fall - BioWorld MedTech

Apr 08, 2025

Apr 07, 2025

Layoff Tracker: Spark Lays Off 298 Employees - BioSpace

Apr 07, 2025

Atara Biotherapeutics stock hits 52-week low at $5.3 - Investing.com

Apr 07, 2025

Apr 04, 2025

How the (ATRA) price action is used to our Advantage - news.stocktradersdaily.com

Apr 04, 2025

Atara Biotherapeutics IncOn March 31, Entered Amendment To Commercialization Agreement With Pierre FabreSEC Filing - MarketScreener

Apr 04, 2025

Epstein-Barr Virus (EBV) Market Growth 2025: Trends, Consumer - openPR.com

Apr 04, 2025

Mar 26, 2025

Atara Biotherapeutics Faces Potential Liquidation: Strategic Decisions Crucial for Investor Outcomes - MSN

Mar 26, 2025

Mar 25, 2025

Long Term Trading Analysis for (ATRA) - news.stocktradersdaily.com

Mar 25, 2025

Mar 23, 2025

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Mar 23, 2025

Mar 19, 2025

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mar 19, 2025

Atara Biotherapeutics (NASDAQ:ATRA) Stock Crosses Below 50 Day Moving Average – Should You Sell? - Defense World

Mar 19, 2025

Mar 17, 2025

Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, Prevalence, Therapies and Companies by DelveInsight - The Globe and Mail

Mar 17, 2025

Mar 15, 2025

(ATRA) Investment Report - news.stocktradersdaily.com

Mar 15, 2025

Mar 13, 2025

Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance

Mar 13, 2025

Mar 12, 2025

Atara Biotherapeutics (NASDAQ:ATRA) Given Buy Rating at Canaccord Genuity Group - Defense World

Mar 12, 2025

Mar 11, 2025

Atara Biotherapeutics: Strategic Focus on Ebvallo BLA Resubmission and Market Position Enhancement - TipRanks

Mar 11, 2025

Mar 10, 2025

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress - BioSpace

Mar 07, 2025